Trial Profile
A Single-Center, Open-Label, Dose-Escalation Phase I Clinical Trial of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein for Injection as an Adjuvant to Chemotherapy in Subjects With Breast Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Feb 2024
Price :
$35
*
At a glance
- Drugs Efbemalenograstim alfa (Primary) ; Cyclophosphamide; Epirubicin
- Indications Neutropenia
- Focus Adverse reactions
- Sponsors Evive Biotech; Generon (Shanghai) Corporation
- 23 Aug 2015 New trial record